Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2017.700 | Circulating microRNA 99b as biomarker for predicting the early development, repair and progression of bone erosions in early rheumatoid arthritis using HR-pQCT |
Prof. TAM Lai Shan 譚麗珊 |
| 2017.295 | The long term renal outcome of biopsy proven paediatric lupus nephritis - a comparison of local and overseas cohort |
Prof. TAM Lai Shan 譚麗珊 |
| 2017.239 | The Hong Kong Psoriatic Arthritis Screening program | Prof. TAM Lai Shan |
| 2017.146 | Circulating microRNAs as biomarkers for predicting the early development, repair and progression of bone erosions in early rheumatoid arthritis using HR-pQCT |
Prof. TAM Lai Shan 譚麗珊 |
| 2015.214 | Prevalence and risk factors for osteoporosis in patients with ankylosing spondylitis in Hong Kong: a cross-sectional cohort study |
Dr. TAM Lai Shan 譚麗珊 |
| 2013.300 | Immunopathological roles of the novel anti-inflammatory cytokine interleukin-35 in the patients with systemic lupus erythematous | Professor TAM Lai Shan |
| 2015.664 | A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs |
Prof. TAM Lai Shan 譚麗珊 |
| 2017.683 | Calprotectin in psoriatic arthritis |
Prof. TAM Lai Shan 譚麗珊 |
| 2016.366 | MicroRNAs as biomarkers for predicting the effect of anti-TNF and anti-IL6 in changes of bone erosions in rheumatoid arthritis using HR-pQCT |
Prof. TAM Lai Shan 譚麗珊 |
| 2014.387 | Coronary atherosclerosis in psoriatic arthritis | Prof. TAM Lai Shan |
| 2016.533 | A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate |
Prof. TAM Lai Shan 譚麗珊 |
| 2016.551 | A Randomized Open-label Study to Evaluate the Efficacy and Safety of Tacrolimus and Corticosteroids in Comparison with Mycophenolate Mofetil and Corticosteroids in Subjects with Class III/IV±V Lupus Nephritis |
Prof. TAM Lai Shan 譚麗珊 |
| 2016.359 | A double-blind, randomised, placebo-controlled trial evaluating the effect of BI 655064 administered as sub-cutaneous injections, on renal response after one year of treatment, in patients with active lupus nephritis |
Prof. TAM Lai Shan 譚麗珊教授 |
| 2025.019 | Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | Prof. TAM Lai Shan |
| 2024.182 | Causal machine learning models for prediction of serious infection events in inflammatory arthritis: a population-based study |
Prof Tam Lai Shan Lai Shan TAM |
| 2024.193 | Lowest Efficacious Dose in Psoriatic Arthritis (LED PsA): A Multicentre Non-inferiority Randomized Open-Label Controlled Trial Assessing b/tsDMARDs Spacing | Prof. TAM Lai Shan |
| 2024.661 | Methotrexate versus TNF inhibition in preventing structural damage in Early Psoriatic Arthritis: A randomized trial using HR-pQCT (MeTEPsA trial) | Prof. TAM Lai Shan |
| 2025.008 | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-naïve Participants with Active Psoriatic Arthritis | Prof. TAM Lai Shan |
| 2024.718 | REMIPPSA: REMISSION STATUS IN PSORIATIC ARTHRITIS FROM THE PATIENT’S PERSPECTIVE. A QUALITATIVE STUDY. | Prof. TAM Lai Shan |
| 2025.247 | Arresting Enthesiophyte and Erosion Progression in PsA: A 5-Year HR-pQCT Study | Prof. TAM Lai Shan |
| 2024.352 | A Phase 3 Randomized, Double-blind, Multi-center, Placebo-controlled Study to Evaluate the Efficacy and Safety of AR882 in Participants with Gout |
Prof. TAM Lai Shan 譚麗珊 |
| 2024.221 | Evaluation of molecular and cellular dysregulation in systemic lupus erythematosus |
Prof. TAM Lai Shan 譚麗珊 |
| 2025.264 | Identifying the optimal erosion volume threshold for predicting rheumatoid arthritis in individuals with arthralgia: a high-resolution peripheral quantitative computed tomography study | Prof. TAM Lai Shan |
| 2019.063 | Effects of tight-control strategy with rosuvastatin on progression of subclinical carotid and coronary atherosclerosis in psoriatic arthritis- a prospective cohort study |
Prof. TAM Lai Shan 譚麗珊 |
| 2020.530 | 5-Year Cardiovascular Event Risk in Early Rheumatoid Arthritis Patients who received Treat-to-Target Management: a population-based cohort study |
Prof. TAM Lai Shan 譚麗珊 |
| 2020.128 | Portable integrated diagnostic platform for chronic auto-immune diseases |
Prof. TAM Lai Shan 譚麗珊 |
| 2018.417 | Prevention of metacarpophalangeal joints structure damage in patients with psoriatic arthritis using tofacitinib | Prof. TAM Lai Shan |
| 2019.540 | A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). |
Dr. TAM Lai Shan 譚麗珊 |
| 2019.224 | Effects of achieving SDAI remission on joint space outcomes progression in early rheumatoid arthritis: an HR-pQCT study |
Prof. TAM Lai Shan 譚麗珊 |
| 2019.650 | Effects of tight-control strategy with and without rosuvastatin on progression of subclinical coronary and carotid atherosclerosis in psoriatic arthritis- a randomized placebo-controlled study |
Prof. TAM Lai Shan 譚麗珊 |
| 2020.129 | Vascular effects of achieving low disease activity in axial spondyloarthritis - a 2-year prospective cohort study |
Prof. TAM Lai Shan 譚麗珊 |
| 2019.573 | Subclinical gut inflammation and gut microbiome in axial spondyloarthritis patients in Hong Kong |
Prof. TAM Lai Shan 譚麗珊 |
| 2020.617 | Subclinical atherosclerosis in axial spondyloarthritis- a cross-sectional study |
Prof. TAM Lai Shan 譚麗珊 |
| 2018.225 | The APLAR Spondyloarthritis (SpA) Registry |
Prof. TAM Lai Shan 譚麗珊 |
| 2020.141 | Quantification of erosion, joint space width and new bone formation using deep learning-based approaches |
Prof. TAM Lai Shan 譚麗珊 |
| 2018.144 | Bone Microarchitecture Assessed by 3D High-resolution Peripheral Quantitative Computed Tomography (HR-pQCT) as predictor of fracture risk in patients with glucocorticoid-induced osteoporosis |
Prof. TAM Lai Shan 譚麗珊 |
| 2020.516 | CUHK Rheumatology Research Centre Imaging Database of Rheumatic Diseases |
Prof. TAM Lai Shan 譚麗珊 |
| 2019.247 | Survival benefit of statin use in patients with immune mediated inflammatory diseases in Hong Kong - A population-based study | Prof. TAM Lai Shan |
| 2019.401 | Immunological role of the ILC2-B lymphocyte regulatory axis in systemic lupus erythematosus |
Prof. TAM Lai Shan 譚麗珊 |
| 2020.519 | Cardiovascular events in axial spondyloarthritis |
Prof. TAM Lai Shan 譚麗珊 |
| 2019.264 | Incidence of and associated factors of infective complications in rheumatology patients taking DMARDs | Dr. TAM Lai Shan |
| 2019.180 | The microbiome study in psoriasis and psoriatic arthropathy patients in Hong Kong |
Prof. TAM Lai Shan 譚麗珊 |
| 2011.558 | RAGE: a new therapeutic target and biomarker of rheumatoid arthritis | Professor Tam Lai-Shan |
| 2009.273 | Diagnostic and Prognostic Values of Anti-Ceclic Citullinated Peptide Antibodies in Chinese Population with Rheumatoid Arthritis | Prof. Tam Lai-Shan |
| 2011.209 | Assessment of PROMIS Fatigue Bank with SLE-specfic items for use in an Asian SLE population in Hong Kong and Singapore | Prof. TAM Lai-Shan |
| 2011.276 | Ankylosing spondylitis vascular study | Prof. TAM Lai-Shan |
| 2012.082 | Periatricular and generalized bone loss in psoriatic arthritis | Prof. Tam Lai-Shan |
| 2011.174 | A stochastic cost-effectiveness analysis of an early inflammatory arthritis clinic in Hong Kong | Prof. TAM Lai-Shan |
| 2009.409 | Traditional Chinese Medicine for Osteoarthritis of the Knee (TCM-OAK): A dose escalation study | Prof Tam Lai-Shan |
| 2011.562 | An Open-Label Long-term Safety Extension Trial for Subjects with Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321 (PEARL-SC) | Professor Tam Lai-Shan |
Page 203 of 265.